A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs UCB 7665 (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 06 Apr 2017 Status changed from not yet recruiting to recruiting.
- 03 Apr 2017 Planned End Date changed from 24 Oct 2018 to 14 Sep 2018.
- 03 Apr 2017 Planned primary completion date changed from 1 Oct 2018 to 6 Jul 2018.